Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis

BACKGROUND: Ibrutinib is a Bruton’s tyrosine-kinase (BTK) inhibitor that is approved as a second-line treatment in chronic lymphocytic leukemia (CLL). While recent trials have demonstrated impressive results for ibrutinib, there remains a paucity of real-world data on its use in the clinical setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuttall, Elisabeth, Tung, Joanna, Trounce, Ellie, Johnston, Rosalynd, Chevassut, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628601/
https://www.ncbi.nlm.nih.gov/pubmed/31372077
http://dx.doi.org/10.2147/JBM.S202286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628601/
https://www.ncbi.nlm.nih.gov/pubmed/31372077
http://dx.doi.org/10.2147/JBM.S202286

Ejemplares similares